Not only does this show Pfizer has huge cash reserves and the ability to pay a fair price for RAP. The offer is a 78% premium on Biohaven's closing share price, while the RAP offer is only a 27.8% premium on the share price. Vote NO!
Valuing ResApp Health, page-40
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #